This study presents a bibliometric analysis of research trends on tumor burden and immunotherapy, revealing key developments and hotspots in this field. A total of 1030 publications from 1987 to 2022 were analyzed, with the United States and China publishing the most articles. The top journals include Cancer Immunology Immunotherapy and Journal for ImmunoTherapy of Cancer. The University of Texas MD Anderson Cancer Center is the leading institution. Hot keywords include 'nivolumab', 'tumor microenvironment', and 'immune checkpoint inhibitor'. Melanoma is the most common tumor type studied. The field is rapidly growing, with increasing emphasis on understanding the relationship between tumor burden and immunotherapy. Key findings include the importance of tumor burden in immunotherapy outcomes, the role of immune checkpoint inhibitors, and the impact of tumor microenvironment on treatment. The analysis also highlights the need for further research into the mechanisms underlying the relationship between tumor burden and immunotherapy, as well as the development of practical indicators for tumor burden assessment. The study underscores the importance of international collaboration and the potential of personalized medicine in improving immunotherapy outcomes. The results provide a comprehensive overview of current research trends and highlight areas for future investigation.This study presents a bibliometric analysis of research trends on tumor burden and immunotherapy, revealing key developments and hotspots in this field. A total of 1030 publications from 1987 to 2022 were analyzed, with the United States and China publishing the most articles. The top journals include Cancer Immunology Immunotherapy and Journal for ImmunoTherapy of Cancer. The University of Texas MD Anderson Cancer Center is the leading institution. Hot keywords include 'nivolumab', 'tumor microenvironment', and 'immune checkpoint inhibitor'. Melanoma is the most common tumor type studied. The field is rapidly growing, with increasing emphasis on understanding the relationship between tumor burden and immunotherapy. Key findings include the importance of tumor burden in immunotherapy outcomes, the role of immune checkpoint inhibitors, and the impact of tumor microenvironment on treatment. The analysis also highlights the need for further research into the mechanisms underlying the relationship between tumor burden and immunotherapy, as well as the development of practical indicators for tumor burden assessment. The study underscores the importance of international collaboration and the potential of personalized medicine in improving immunotherapy outcomes. The results provide a comprehensive overview of current research trends and highlight areas for future investigation.